# Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

> **NCT00036556** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 941 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Atrasentan

## Key facts

- **NCT ID:** NCT00036556
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 941 (ACTUAL)
- **Last updated:** 2007-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036556, "Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00036556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*